- Home
- SRBK vs MAIA Comparison
SRBK vs MAIA Comparison
Compare SRBK & MAIA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SRBK
- MAIA
- Stock Information
- Founded
- SRBK 1887
- MAIA 2018
- Country
- SRBK United States
- MAIA United States
- Employees
- SRBK N/A
- MAIA N/A
- Industry
- SRBK
- MAIA Biotechnology: Pharmaceutical Preparations
- Sector
- SRBK
- MAIA Health Care
- Exchange
- SRBK Nasdaq
- MAIA Nasdaq
- Market Cap
- SRBK 117.4M
- MAIA 46.7M
- IPO Year
- SRBK N/A
- MAIA 2022
- Fundamental
- Price
- SRBK $14.43
- MAIA $1.88
- Analyst Decision
- SRBK
- MAIA
- Analyst Count
- SRBK 0
- MAIA 0
- Target Price
- SRBK N/A
- MAIA N/A
- AVG Volume (30 Days)
- SRBK 115.0K
- MAIA 529.1K
- Earning Date
- SRBK 07-25-2025
- MAIA 08-08-2025
- Dividend Yield
- SRBK 1.38%
- MAIA N/A
- EPS Growth
- SRBK N/A
- MAIA N/A
- EPS
- SRBK N/A
- MAIA N/A
- Revenue
- SRBK $27,988,000.00
- MAIA N/A
- Revenue This Year
- SRBK N/A
- MAIA N/A
- Revenue Next Year
- SRBK N/A
- MAIA N/A
- P/E Ratio
- SRBK N/A
- MAIA N/A
- Revenue Growth
- SRBK 23.80
- MAIA N/A
- 52 Week Low
- SRBK $9.23
- MAIA $1.40
- 52 Week High
- SRBK $14.96
- MAIA $4.24
- Technical
- Relative Strength Index (RSI)
- SRBK 78.62
- MAIA 56.41
- Support Level
- SRBK $13.46
- MAIA $1.80
- Resistance Level
- SRBK $14.96
- MAIA $2.15
- Average True Range (ATR)
- SRBK 0.25
- MAIA 0.13
- MACD
- SRBK 0.12
- MAIA 0.02
- Stochastic Oscillator
- SRBK 74.76
- MAIA 60.00
About SRBK SR Bancorp Inc. Common stock
SR Bancorp Inc principal business is to acquire deposits from individuals and businesses in the communities surrounding offices and to use these deposits to fund loans.
About MAIA MAIA Biotechnology Inc.
MAIA Biotechnology Inc is a clinical-stage biopharmaceutical company developing targeted immunotherapies for cancer. THIO (6-thio-dG or 6-thio-2 '-deoxyguanosine), its lead asset, is an investigational dual mechanism of action drug candidate incorporating telomere targeting and immunogenicity. Patients with advanced NSCLC will be treated first with THIO followed a few days later by the immune checkpoint inhibitor Libtayo (cemiplimab), manufactured and commercialized by Regeneron.